Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04420754
Other study ID # 19-12021154
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 28, 2020
Est. completion date December 2024

Study information

Verified date November 2023
Source AffyImmune Therapeutics, Inc.
Contact Sonal Gupta, MD PhD
Phone 508-654-3600
Email sgupta@affyimmune.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.


Description:

The primary objective of this study is to assess the safety and tolerability of AIC100 CAR T Cells and determine the recommended Phase 2 dose of AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer and in patients with anaplastic thyroid cancer that are BRAF wild-type, including newly diagnosed, or BRAF mutant anaplastic thyroid cancer after failure of BRAF mutant specific therapy. Upon enrollment, patients will undergo apheresis for collection of autologous lymphocytes. The autologous T cells will be transfected and expanded in vitro to generate the AIC100 CAR T Cell product. After lymphodepleting chemotherapy, AIC100 CAR T Cells will be infused. The study drug product, AIC100, consists of autologous CAR T cells targeting intercellular adhesion molecule-1 (ICAM-1) on thyroid cancer. In addition, AIC100 cells express the somatostatin receptor subtype 2 (SSTR2), which should enable imaging of AIC100 CAR T Cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2024
Est. primary completion date June 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Willing and able to participate in the study and provide written informed consent 2. Be = 18 years of age on the day of signing the Informed Consent Form 3. Patients must have thyroid cancer that expresses ICAM-1 and that meets one of the following diagnoses: 1. Anaplastic Thyroid Cancer BRAF wild-type at any stage, including newly diagnosed 2. Anaplastic Thyroid Cancer BRAF mutant after failure of or inability to tolerate BRAF- specific therapy 3. Poorly Differentiated Thyroid Cancer that has failed any of the following treatments: surgery radioactive iodine, chemotherapy, radiation therapy, and/or targeted therapies 4. Measurable disease by Computed Tomography (CT) or Positron Emission Tomography (PET) PET/CT per RECIST v1.1 a. For ATC patients who do not have measurable disease at Screening, they are required to have measurable disease at Baseline Day -7 to proceed in the study. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 6. Life expectancy greater than 8 weeks 7. Overall adequate hepatic, renal, bone marrow, cardiac, and coagulation function, defined as the following: 1. Estimated creatinine clearance = 50 mL/minute 2. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST): normal or Grade 1. Note: Lymphodepleting Chemotherapy (LDC) agents can cause fluctuations in hepatic enzymes. 3. Serum total bilirubin: normal or Grade 1. Note: LDC agents can cause fluctuations in hepatic enzymes. 4. Serum albumin: normal or Grade 1. (human albumin supplementation is not allowed within 2 weeks prior to Screening assessment) 5. Hemodynamically stable and left ventricular ejection fraction = 45% 6. Hematological parameters i. Absolute neutrophil count > 1000/µL without myeloid growth factor support for = 2 weeks ii. Absolute lymphocyte count = 100/µL at screening and at apheresis iii. Platelet count = 50 × 1000/µL without platelet transfusion for = 2 weeks iv. Hemoglobin concentration > 8 g/dL without red blood cell transfusion for = 2 weeks 8. Has met the minimum washout time for previous cancer treatments before undergoing apheresis or LDC, and in the Investigator's judgement, the patient is able to safely undergo the procedure 9. (incorporated into inclusion criterion #7) 10. Females of reproductive potential (defined as all females physiologically capable of becoming pregnant) must agree to use 1 highly effective method of contraception and 1 additional effective method from at least 28 days before enrollment/apheresis and for at least 1 year after the infusion of AIC100 CAR T Cells. 11. Females of reproductive potential must have a negative serum beta-human chorionic gonadotropin pregnancy test result at Screening 12. (incorporated into inclusion criterion #3) Exclusion Criteria: 1. Women who are pregnant or breastfeeding 2. Clinically significant, active, uncontrolled, systemic infection; the following are not exclusionary: 1. Patients with HIV must have been on effective antiretroviral therapy for = 4 weeks prior to enrollment; must have an HIV viral load < 400 copies/µL; no acquired immunodeficiency syndrome related opportunistic infections in the previous 12 months; and a CD4+ cell count = 350 cells/µL 2. Patients with chronic hepatitis B virus (HBV) infection must be on antiviral therapy and have an HBV viral load below the limits of detection 3. Patients with chronic hepatitis C virus (HCV) infection must have completed therapy and have an HCV viral load below the limits of detection 3. Prior treatment with investigational gene therapy or CAR T cell therapy 4. Presence of active and clinically relevant central nervous system disorder such as epilepsy, stroke, or symptomatic or uncontrolled brain metastases 5. Evidence of another malignancy within 2 years prior to Screening (except in-situ non melanoma skin cancers, localized controlled prostate cancer, adequately treated Stage 1 uterine cancer that has a low risk of recurrence, or any other malignancies with similar outcome) 6. (incorporated into exclusion criterion #2) 7. Active autoimmune disease (including but not limited to systemic lupus erythematosus, Sjögren's Syndrome, rheumatoid arthritis (RA), psoriasis, multiple sclerosis, inflammatory bowel disease) requiring immunosuppressive therapy within 4 weeks prior to eligibility confirmation 8. Patients with severe chronic diseases of the kidney, liver, heart, lung; or any other serious illness that, in the opinion of the Investigator, may affect the patient's treatment, follow up, or assessments, including but not limited to uncontrolled clinically significant neurological or psychiatric disorders or metabolic diseases 9. Patients who need long-term use of systemic corticosteroids > 10 mg/day prednisone or equivalent 10. Allergy to any of the chemotherapy drugs given during lymphodepletion or known hypersensitivity to any component of AIC100 CAR T Cells, including excipients 11. Receipt of a COVID-19 vaccine within 4 weeks before Screening 12. Concurrent participation in another interventional clinical study during participation in this study 1. Prior treatment with any gene therapy or genetically modified cell therapy, including CAR T cells 2. Prior treatment with ICAM-1 directed antibody, bispecific T cell engager, or antibody drug conjugate, unless there is confirmed ICAM-1 expression (by immunohistochemistry) after progression or relapse following most recent ICAM-1 directed treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AIC100 CAR T Cells
Autologous CAR T cells directed against ICAM-1

Locations

Country Name City State
United States Northwestern Memorial Hospital Chicago Illinois
United States City of Hope National Medical Center, City of Hope Medical Center Duarte California
United States MD Anderson Cancer Center Houston Texas
United States Weill Cornell Medical College New York New York

Sponsors (1)

Lead Sponsor Collaborator
AffyImmune Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of overall Grade >=3 Adverse Events (AE) and Serious Adverse Events (SAE) The number of Grade 3, 4 and 5 AEs and SAEs that occur throughout the study. Up to 15 years post-infusion
Primary Incidence of anticipated AIC100 CAR T Cell related AEs, SAEs and adverse events of special interest (AESI) The number of CAR T related adverse events that occur throughout the study, including AESIs, infusion-related reactions, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), tumor lysis syndrome (TLS) and new malignancies. Up to 15 years post-infusion
Primary Determine recommended phase 2 dose The recommended phase 2 dose will be determined through the dose escalation process Up to 15 years post-infusion
Secondary Assessment of presence and frequency of AIC100 CAR T cells in peripheral blood and tumor samples (when available) Patients will be monitored for expansion and persistence of AIC100 CAR transgenes after infusion by vector copy number (VCN) analysis Up to 15 years post-infusion
See also
  Status Clinical Trial Phase
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Withdrawn NCT01701349 - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Phase 3
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Terminated NCT00603941 - A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel Phase 1/Phase 2
Completed NCT00280852 - Review of Multimodality Management of Anaplastic Thyroid Cancer N/A
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06079333 - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) Phase 2